A Rapid and Sensitive UPLC-MS/MS Method for the Determination of Bellidifolin and Pharmacokinetics Study of Bellidifolin Nano-microcells

Abstract

Background: Bellidifolin (BEL) has a decent enemy of myocardial fibrosis impact, and its preparation into nano-micelles can build security and great biocompatibility in vitro and in vivo. The pharmacokinetic assessment of BEL can be utilized as the reason for the security and viability of BEL in clinical use. Objective: This research aimed to establish an effective UPLC-MS/MS strategy for assuring BEL in rodent plasma and concentrating on its pharmacokinetics in vivo. Methods: Luteolin was utilized as an internal standard (IS). Chromatographic separation was accomplished utilizing a UPLC HSS T3 column (2.1 ×100 mm, 1.8 μm) section using a mobile phase of 0.1% acetonitrile (A) and 0.1% formic acid in water (B) with gradient elution. Electrospray ionization (ESI) coupled mass spectrometry was applied in various response checking (MRM) modes with negative ionization. Results: The pharmacokinetic behaviour of bellidifolin nano-micelles in vivo showed that the peak concentration (Cmax) was 1666.19±479.92 μg/L, the time to peak (Tmax) was 0.167 h, and the apparent elimination half-life (t1/2) was 7.60±3.58 h. The plasma clearance rate (CL/F) was 1.15±0.48 L/h/kg, the apparent volume of distribution (V/F) was 14.38±11.04, the area under the curve (AUC) was 8292.57±4193.13 μg/L*h, and the mean retention time (MRT) was 9.70±4.55 h. Conclusion: The method was successfully applied to the plasma pharmacokinetics of bellidifolin nano-micelles after intragastric administration to rats.